EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A CRISPR-Cas13b System Degrades SARS-CoV and SARS-CoV-2 RNA In Vitro

Klara Andersson, Ani Azatyan iD, Martin Ekenberg, Gözde Güçlüler, Laura Sardon Puig, Marjo Puumalainen, Theodor Pramer, Vanessa M Monteil iD, Ali Mirazimi

Viruses · 2024

DOI: 10.3390/v16101539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Klara Andersson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden. Hauptthemen laut MEDLINE: SARS-CoV-2, CRISPR-Cas Systems, RNA, Viral, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institutet, Stiftelsen för Strategisk Forskning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a time of climate change, population growth, and globalization, the risk of viral spread has significantly increased. The 21st century has already witnessed outbreaks of Severe Acute Respiratory Syndrome virus (SARS-CoV), Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2), Ebola virus and Influenza virus, among others. Viruses rapidly adapt and evade human immune systems, complicating the development of effective antiviral countermeasures. Consequently, the need for novel antivirals resilient to viral mutations is urgent. In this study, we developed a CRISPR-Cas13b system to target SARS-CoV-2. Interestingly, this system was also efficient against SARS-CoV, demonstrating broad-spectrum potential. Our findings highlight CRISPR-Cas13b as a promising tool for antiviral therapeutics, underscoring its potential in RNA-virus-associated pandemic responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2CRISPR-Cas SystemsRNA, ViralCOVID-19Severe acute respiratory syndrome-related coronavirusHumansAntiviral Agents

Stichwörter der Autor:innen

CRISPR-Cas13bSARS-CoVSARS-CoV-2antiviral development

Substanzen

RNA, ViralAntiviral Agents

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.
  • Public Health Agency of Sweden, 17182 Solna, Sweden.
  • National Veterinary Institute, 75189 Uppsala, Sweden.

ORCID-Profile: Ani Azatyan, Vanessa M Monteil

Förderung

  • Karolinska Institutet
  • Stiftelsen för Strategisk Forskning

Zitieren

APA

Andersson, K., Azatyan, A., Ekenberg, M., Güçlüler, G., Sardon Puig, L., Puumalainen, M., Pramer, T., Monteil, V. M., & Mirazimi, A. (2024). A CRISPR-Cas13b System Degrades SARS-CoV and SARS-CoV-2 RNA In Vitro. Viruses. https://doi.org/10.3390/v16101539

Vancouver

Andersson K, Azatyan A, Ekenberg M, Güçlüler G, Sardon Puig L, Puumalainen M, et al. A CRISPR-Cas13b System Degrades SARS-CoV and SARS-CoV-2 RNA In Vitro. Viruses. 2024. doi:10.3390/v16101539

BibTeX
@article{Andersson2024,
  author = {Andersson, Klara and Azatyan, Ani and Ekenberg, Martin and Güçlüler, Gözde and Sardon Puig, Laura and Puumalainen, Marjo and Pramer, Theodor and Monteil, Vanessa M and Mirazimi, Ali},
  title = {A CRISPR-Cas13b System Degrades SARS-CoV and SARS-CoV-2 RNA In Vitro},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16101539}
}
Kostenlos starten →